Peter Attia· MD
8% of cancers have a BRAF mutation, which is intrinsic in the MAP kinase pathway. It's the most popular point of mutation in that pathway.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
8% of cancers have a BRAF mutation, which is intrinsic in the MAP kinase pathway. It's the most popular point of mutation in that pathway.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So the big headline from that Nature paper was rarely ever do you see a C-RAF. Yeah, rare C-RAF. 8% of all cancer was the estimate when they sequenced 484 tumors. ARAF rarely, if ever, mutated. So BRAF was the one.
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.